Treprostinil

Known as: treprostinil [Chemical/Ingredient], (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid, Treprostinilo 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
010203020022018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVES This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Pulmonary arterial hypertension (PAH) remains a poorly understood and frequently lethal disease with few treatment… (More)
Is this relevant?
2007
2007
BACKGROUND Chronic thromboembolic pulmonary hypertension (CTEPH) results from non-resolving pulmonary thromboemboli that are… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exercise capacity and… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Pulmonary arterial hypertension (PAH) is a life-threatening disease for which both continuous IV epoprostenol and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
RATIONALE Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension. The… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
STUDY OBJECTIVES To assess the efficacy and safety of continuous subcutaneous infusion of treprostinil, a stable prostacyclin… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be… (More)
Is this relevant?